Regeneron Builds on Sanofi Partnership in Strong Q3 Earnings
Published . Updated .
Market Call
Think this story will push the stock up or down over the next three trading days? Make a free call and see what other readers think. Points are play money with no cash value.
Get these market calls by email
The week's biggest market-moving stories, Congress trades and Trump posts, with the tickers they touch. Free, one email a week.
Free. We only use your email to send the digest, never sell or share it, and every email has a one-click unsubscribe link. See our privacy policy.
This report does not map to a usual set of affected companies.
Directly affected
- SNY Sanofi
Named in this report.
Indirectly affected
- XLV Health Care Select Sector SPDR
Health Care Select Sector SPDR holds the health sector that Sanofi belongs to, so it often moves with news about it.
- NVS Novartis AG-0.1% 14d
Novartis AG is a peer of Sanofi in pharmaceutical preparations; rivals often move on the same news.
- AZN AstraZeneca+14.8% 30d
AstraZeneca is a peer of Sanofi in pharmaceutical preparations; rivals often move on the same news.
- NVO Novo Nordisk A/S-10.5% 30d
Novo Nordisk A/S is a peer of Sanofi in pharmaceutical preparations; rivals often move on the same news.
- GSK Gsk-8.1% 7d
Gsk is a peer of Sanofi in pharmaceutical preparations; rivals often move on the same news.
- ROIV Roivant Sciences+9.5% 12d
Roivant Sciences is a peer of Sanofi in pharmaceutical preparations; rivals often move on the same news.
Price reaction, T-5 to T+3
| Ticker | T-5 | T-3 | T-1 | T0 | T+1 | T+2 | T+3 |
|---|---|---|---|---|---|---|---|
| SNY | -5.83% | -4.80% | base | +2.61% | +2.15% | +6.92% | +5.33% |
| XLV | -3.03% | -2.77% | base | -0.14% | -0.48% | +2.59% | +0.17% |
| NVS | -4.37% | -2.94% | base | +0.39% | -0.98% | +2.61% | +0.59% |
| AZN | -7.79% | -9.17% | base | -0.02% | -1.47% | +1.27% | +0.29% |
| NVO | -2.16% | -4.29% | base | +1.15% | +0.54% | +5.44% | +0.18% |
| GSK | +3.20% | -1.53% | base | -0.79% | -1.58% | +3.29% | +1.72% |
| ROIV | -2.30% | +0.50% | base | -2.76% | -2.30% | +3.55% | -0.76% |
Closing-price change versus T-1, the last close before the story. T0 to T+3 fill in after each market close. Prices: Alpaca IEX.
Regeneron Builds on Sanofi Partnership in Strong Q3 Earnings Healthcare Digital
Source: Healthcare Digital
This story
| Company | When | Move | Status |
|---|---|---|---|
| AZN | that day | -0.02% | final price |
| AZN | the next day | -1.47% | final price |
| AZN | two days later | +1.27% | final price |
| AZN | three days later | +0.29% | final price |
| AZN | three days earlier | -9.17% | final price |
| AZN | five days earlier | -7.79% | final price |
| GSK | that day | -0.79% | final price |
| GSK | the next day | -1.58% | final price |
| GSK | two days later | +3.29% | final price |
| GSK | three days later | +1.72% | final price |
| GSK | three days earlier | -1.53% | final price |
| GSK | five days earlier | +3.20% | final price |
| NVO | that day | +1.15% | final price |
| NVO | the next day | +0.54% | final price |
| NVO | two days later | +5.44% | final price |
| NVO | three days later | +0.18% | final price |
| NVO | three days earlier | -4.29% | final price |
| NVO | five days earlier | -2.16% | final price |
| NVS | that day | +0.39% | final price |
| NVS | the next day | -0.98% | final price |
| NVS | two days later | +2.61% | final price |
| NVS | three days later | +0.59% | final price |
| NVS | three days earlier | -2.94% | final price |
| NVS | five days earlier | -4.37% | final price |
| ROIV | that day | -2.76% | final price |
| ROIV | the next day | -2.30% | final price |
| ROIV | two days later | +3.55% | final price |
| ROIV | three days later | -0.76% | final price |
| ROIV | three days earlier | +0.50% | final price |
| ROIV | five days earlier | -2.30% | final price |
| SNY | that day | +2.61% | final price |
| SNY | the next day | +2.15% | final price |
| SNY | two days later | +6.92% | final price |
| SNY | three days later | +5.33% | final price |
| SNY | three days earlier | -4.80% | final price |
| SNY | five days earlier | -5.83% | final price |
| XLV | that day | -0.14% | final price |
| XLV | the next day | -0.48% | final price |
| XLV | two days later | +2.59% | final price |
| XLV | three days later | +0.17% | final price |
| XLV | three days earlier | -2.77% | final price |
| XLV | five days earlier | -3.03% | final price |
Congressional trades in the stocks in this story
- Rep. Kevin Hern sold Novartis Ag (NVS), worth $15,001 - $50,000 on 27 Aug 2026. That is 67 days before publication. Filed 25 Sep 2026. View the filing.
- Rep. Kevin Hern sold Novo Nordisk A S (NVO), worth $1,001 - $15,000 on 10 Sep 2026. That is 53 days before publication. Filed 25 Sep 2026. View the filing.
- Rep. Kevin Hern sold Novo Nordisk A S (NVO), worth $1,001 - $15,000 on 31 Aug 2026. That is 63 days before publication. Filed 25 Sep 2026. View the filing.
- Rep. Scott Scott Franklin bought Novo Nordisk A S (NVO), worth $1,001 - $15,000 on 26 Aug 2026. That is 68 days before publication. Filed 17 Sep 2026. View the filing.
Public disclosure filings, not a recommendation. The filing link is the source document. News use of these reports still sits under 5 U.S.C. § 13107(c).
How solid “Regeneron Builds on Sanofi Partnership in Strong Q3 Earnings” looks
12 out of 100
“Regeneron Builds on Sanofi Partnership in Strong Q3 Earnings” scores 12 out of 100. The score uses 1 sources.